AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board.
During the past 18 years, Buxfeldt’s career has seen him work on a variety of disease areas, supporting more than 30 molecules/brands in global positions.
He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.
Dr Werner Van den Eynde, vice president for the NDA advisory board, said: “We are very happy to welcome Claes on board as our new HTA director.
“Claes’ expertise will allow us to provide an even better service to our clients.”
Buxfeldt’s new role at NDA will see him drive and develop the group’s service offerings in the HTA area.